OKYO Pharma Ltd ADR Asset Resilience Ratio
OKYO Pharma Ltd ADR asset resilience ratio. OKYO Pharma Ltd ADR (OKYO) has an Asset Resilience Ratio of 28.60% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can OKYO Pharma Ltd ADR fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of OKYO Pharma Ltd ADR (2009–2026)
Asset resilience ratio of OKYO Pharma Ltd ADR from 2009 to 2026. This chart shows how OKYO Pharma Ltd ADR's Asset Resilience Ratio has changed over time. Read debt load of OKYO Pharma Ltd ADR for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down OKYO Pharma Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see OKYO Pharma Ltd ADR asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $6.00 Million | 28.6% |
| Total Liquid Assets | $6.00 Million | 28.60% |
Asset Resilience Insights
- Very High Liquidity: OKYO Pharma Ltd ADR maintains exceptional liquid asset reserves at 28.60% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
OKYO Pharma Ltd ADR Industry Peers by Asset Resilience Ratio
Compare OKYO Pharma Ltd ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
OKYO Pharma Ltd ADR Asset Resilience Ratio by Year (2009–2026)
OKYO Pharma Ltd ADR asset resilience ratio by year from 2009 to 2026. The table below shows the annual Asset Resilience Ratio data for OKYO Pharma Ltd ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 28.60% | $6.00 Million | $20.98 Million | -- |
| 2025-03-31 | 0.00% | $0.00 | $3.68 Million | -- |
| 2017-03-31 | 60.74% | $16.86 Million | $27.76 Million | +9.96pp |
| 2010-03-31 | 50.77% | $27.49 Million | $54.13 Million | -15.22pp |
| 2009-03-31 | 65.99% | $25.25 Million | $38.27 Million | -- |
About OKYO Pharma Ltd ADR
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to t… Read more